ST. JOSEPH, Mich., June 24 /PRNewswire/ -- GeneGo, Inc., the leading systems biology tools company, announced today that VTT has licensed MetaCore(TM). VTT develops novel high-throughput methods for cancer research, drug discovery and diagnostics. The focus is in investigating mechanisms of cancer development and progression, identification of therapeutic targets and exploration of the mechanism of action of anti-cancer compounds. VTT will utilize MetaCore and MetaDrug in high-throughput compound screening, RNA interference experiments, cell biology and bioinformatics projects to identify pathways and networks important in translational cancer research.
There are 85 researchers and staff members working in VTT's Medical Biotechnology Knowledge Centre in Turku. The research is funded by the European Commission and the Academy of Finland. VTT accommodates two EU Marie Curie Centre of Excellence teams and coordinates the Academy of Finland Centre of Excellence for translational genome-wide biology. Further information on VTT: http://www.vtt.fi.
"VTT was our first customer in Finland and an important internationally recognized cancer research center," said Julie Bryant, GeneGo's VP of Business development. "We have seen a growing need for analysis platforms focused in disease areas recently. We responded by developing disease pathway ontologies, biomarker and drug databases and new interactome analysis tools. We are pleased that our expertise in cancer is appreciated by professional molecular oncologists at VTT."
About GeneGo, Inc.
GeneGo, Inc. systems biology technology for life science research. The original computational MetaDiscovery(TM) platform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, proteomics, metabolomics, microRNA assays and other phenotypic data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of curated biological pathways and networks. GeneGo's flagship product, MetaCore 4.7(TM), assists pharmaceutical scientists in the areas of target selection and validation, identification of biomarkers for disease states and toxicology. The second product, MetaDrug 4.7(TM) is designed for prediction of human metabolism, toxicity and biological effects for novel small molecules compounds. MetaBase(TM) represents the knowledge base for MetaCore. For more information, please visit the company's web site at http://www.genego.com
MetaCore(TM), MetaBase(TM), MetaDrug(TM), MetaLink(TM), MetaDiscovery(TM), MetaTox(TM), MetaMiner(TM) and 1-2-3 Workflow(TM) are trademarks of GeneGo, Inc.
|SOURCE GeneGo, Inc.|
Copyright©2008 PR Newswire.
All rights reserved